Mitochondrial dysfunction has been identified as an important factor in diseases ranging from neurodegenerative conditions (ALS, Alzheimer’s, Parkinson’s Disease), epilepsy, psychiatric illness and autism, to cardiovascular disease, liver/kidney disease, diabetes and cancer. The wide-ranging impact of mitochondria in so many diseases makes them prime targets for therapeutics.
Additionally, medications for many diseases cause unwanted toxicity to the mitochondria. Mitochondrial toxicity is one of the leading causes of attrition in the drug development process, as well as in post-market drug withdrawals. Targeting Mitochondrial Dysfunction & Toxicity (the first conference of its kind in the US) will present the latest research in new targeting pathways, novel therapeutics, and methods to decrease or eliminate mitochondrial toxicity when developing therapeutics for many indications.
The conference will feature research presentations from:
- Center for Mitochondrial and Epigenomic Medicine, Children’s Hospital of Philadelphia and University of Pennsylvania
- Neuropsychopharmacology Laboratory, Mayo Clinic
- Mitochondrial Research, Nestlé Institute of Health Sciences, Switzerland Astellas Research Institute of America LLC
- Muscle Diseases Group, Novartis Institutes for Biomedical Research
- GALLY International Biomedical Research Consulting LLC
- Cell-Based Assays and Mitochondrial Biology, Pfizer R & D
- Pioneer Valley Life Sciences Institute
- Institute of Translational Medicine, The University of Liverpool
- Safety Prediction, Worldwide Medicinal Chemistry, Pfizer, Inc.
- Lilly Research Laboratories
- Elliott-Barnett-Head Breast Cancer Research and Treatment
- Biochemistry and Molecular Biology, Dalhousie University
- University of Arizona
- Metabolic Solutions Development Company